The Four Phases of Clinical Drug Trials

Phase I: Initial Testing in Healthy Volunteers

In the first phase of the clinical trial, the new active substance is tested in humans for the first time. The participants, also referred to as volunteers, are usually young and healthy—only rarely is the investigational drug administered to patients at this stage. This may be the case, for example, if no effective treatment is available for a particular disease or if its effects on a specific condition are to be explored.

The primary purpose of Phase I clinical trials is to assess the tolerability and safety of the new drug. Researchers evaluate which organs and processes in the body are affected by the active substance, how concentrated it is in the bloodstream, and how quickly it is eliminated from the body. Based on these data, the appropriate dosage of the new drug can be determined. In addition, conclusions can be drawn about the most effective and reliable route of administration.

This phase of the clinical trial typically lasts from several weeks to several months and involves approximately 20 to 80 volunteer participants. Since the effects on the human body cannot yet be reliably predicted, participants are closely and continuously monitored.

Phase II: Evaluation of Efficacy and Dosage

In the second phase of the clinical trial, the drug is tested for the first time in patients who have the target condition. The main objectives are to determine whether the desired effect is achieved and how well the drug is tolerated. In addition to confirming the findings from Phase I, this stage primarily focuses on optimizing the dosage of the active substance; it is therefore also referred to as a “dose-finding trial.”

Approximately 100 to 500 volunteer participants take part in a Phase II clinical trial, which typically lasts several months. As in Phase I, participants are carefully monitored, and treatment can be discontinued immediately if adverse effects occur. After successful completion, the clinical trial proceeds to Phase III.

Phase III: Large-Scale Trials Prior to Approval

The third phase of the clinical trial is conducted under conditions that closely reflect real-world practice. It involves approximately 200 to 10,000 patients who are selected according to strictly defined inclusion and exclusion criteria. The data collected in this phase form the basis for the eventual approval of the new drug.

The primary focus is to confirm efficacy in a large patient population. In addition, interactions with other drugs and the frequency of side effects are evaluated. Participants are usually divided into two groups: one receives the new drug, while the other receives either an existing standard treatment or an inactive placebo. The assignment of patients is typically random, which is referred to as a randomized controlled trial.

In a double-blind trial, neither the treating physicians nor the patients know who is receiving the new active substance until the trial is completed. Approval can only be granted if the data from these comparative trials demonstrate convincing results in terms of efficacy, safety, and benefit–risk profile.

A Phase III clinical trial generally lasts from several months to several years. After successful completion, an application for approval is submitted to the relevant regulatory authority. Once approval is granted, the drug can be prescribed and marketed.

Phase IV: Long-Term Monitoring After Market Introduction

In the fourth phase of clinical trials, the performance of the already approved drug is evaluated under real-world conditions. A Phase IV clinical trial typically runs for several years and involves several thousand participants.

The drug is now also available to patients who were previously excluded from earlier clinical trials due to strict criteria. This includes, for example, children, older adults, and individuals with multiple conditions who require various medications.

The main goal of this phase is to confirm the therapeutic effectiveness in a very large patient population. It also allows for the identification of rare side effects and previously unknown interactions with other drugs. In addition, the data provide insights into potential risks associated with long-term use and possible applications for other conditions.